DYAI
Get informed when a big investor buys or sells
+ FollowOvervalued by 189.9% based on the discounted cash flow analysis.
| Market cap | $15.99 Million |
|---|---|
| Enterprise Value | $21.17 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.23 |
| Beta | 1.15 |
| Outstanding Shares | 36,438,703 |
| P/E Ratio | -1.87 |
|---|---|
| PEG | -10.16 |
| Price to Sales | - |
| Price to Book Ratio | -0.4 |
| Enterprise Value to Revenue | 4.69 |
| Enterprise Value to EBIT | -2.83 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.31 |
| Debt to Equity | -2.77 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | 68,800▼ 5.62% |
| Total Puts | - |
Holdings and activity of institutional investors.
| Ownership % | 12.69%▼ 1.43% |
|---|---|
| Total Invested | $4.14M▼ 1.67% |
| Investors Holding | 40▲ 3.00% |
No data
Dyadic International, Inc. is a global biotechnology company which is developing what it believes will be a potentially significant biopharmaceutical gene expression platform based on the fungus Thermothelomyces heterothallica (formerly ...